Nkarta Therapeutics was founded on the proprietary, robust and well characterized Natural Killer (NK) cell expansion technology pioneered by Dr. Dario Campana. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. Nkarta is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. Nkarta's goal is to develop off-the-shelf NK cell therapy product candidates to improve outcomes for patients.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/05/19 | $114,000,000 | Series B |
Amgen Business Development Deerfield Management Company, L.P. Life Sciences Partners Logos Capital NEA Ventures Novo Holdings RA Capital Samsara BioCapital  SR One | undisclosed |
